2.1
Darolutamide (Nubeqa, Bayer) is indicated for 'the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy'.
2 Information about darolutamide
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for darolutamide.
Price
2.3
The list price of darolutamide is £4,040.00 for a 28‑day supply of 112 x 300 mg tablets (excluding VAT, BNF online accessed September 2025).
2.4
The company has a commercial arrangement. This makes darolutamide available to the NHS with a discount. The size of the discount is commercial in confidence.
Carbon Reduction Plan
2.5
For information, the Carbon Reduction Plan for UK carbon emissions is published on Bayer's Climate Commitment: Net Zero by 2050 webpage.